LV11183B - Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof - Google Patents

Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof Download PDF

Info

Publication number
LV11183B
LV11183B LVP-95-341A LV950341A LV11183B LV 11183 B LV11183 B LV 11183B LV 950341 A LV950341 A LV 950341A LV 11183 B LV11183 B LV 11183B
Authority
LV
Latvia
Prior art keywords
esters
derivative
hydroxy
active ingredient
des
Prior art date
Application number
LVP-95-341A
Other languages
English (en)
Latvian (lv)
Other versions
LV11183A (lv
Inventor
Michel Lanquetin
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of LV11183A publication Critical patent/LV11183A/xx
Publication of LV11183B publication Critical patent/LV11183B/lv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0018Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J11/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-95-341A 1990-11-12 1995-11-14 Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof LV11183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (2)

Publication Number Publication Date
LV11183A LV11183A (lv) 1996-04-20
LV11183B true LV11183B (en) 1996-10-20

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-341A LV11183B (en) 1990-11-12 1995-11-14 Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof

Country Status (17)

Country Link
US (1) US5266712A (es)
EP (1) EP0510167B1 (es)
JP (1) JP3281954B2 (es)
KR (1) KR100196895B1 (es)
AT (1) ATE126806T1 (es)
BR (1) BR9106012A (es)
CA (1) CA2073760C (es)
DE (1) DE69112379T2 (es)
DK (1) DK0510167T3 (es)
ES (1) ES2079172T3 (es)
FI (1) FI111545B (es)
FR (1) FR2668945B1 (es)
GR (1) GR3018117T3 (es)
HU (1) HU212780B (es)
LV (1) LV11183B (es)
RU (1) RU2126013C1 (es)
WO (1) WO1992008730A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) * 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
BRPI0116793B8 (pt) * 2000-12-14 2021-05-25 Johnson & Johnson produtos de hormônio de esteróide e métodos para prepará-los
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
TW200825093A (en) * 2006-08-03 2008-06-16 Teva Pharma Process for preparing clopidogrel bisulphate
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
MX358435B (es) * 2012-06-18 2018-08-03 Therapeuticsmd Inc Capsula de estradiol soluble para insercion por via vaginal.
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series

Also Published As

Publication number Publication date
US5266712A (en) 1993-11-30
EP0510167A1 (fr) 1992-10-28
CA2073760A1 (fr) 1992-05-13
DE69112379D1 (de) 1995-09-28
GR3018117T3 (en) 1996-02-29
DK0510167T3 (da) 1996-01-02
BR9106012A (pt) 1993-01-05
FI923188A0 (fi) 1992-07-10
KR100196895B1 (ko) 1999-06-15
EP0510167B1 (fr) 1995-08-23
ATE126806T1 (de) 1995-09-15
DE69112379T2 (de) 1996-03-28
CA2073760C (fr) 2003-09-23
WO1992008730A1 (fr) 1992-05-29
JPH05503305A (ja) 1993-06-03
HU212780B (en) 1996-11-28
ES2079172T3 (es) 1996-01-01
FR2668945B1 (fr) 1993-02-19
FI923188A (fi) 1992-07-10
KR927003617A (ko) 1992-12-18
FI111545B (fi) 2003-08-15
HU9202608D0 (en) 1992-10-28
JP3281954B2 (ja) 2002-05-13
RU2126013C1 (ru) 1999-02-10
LV11183A (lv) 1996-04-20
HUT61319A (en) 1992-12-28
FR2668945A1 (fr) 1992-05-15

Similar Documents

Publication Publication Date Title
LV11183B (en) Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof
EP2085075B1 (en) Stable shaped particles of crystalline organic compounds
EP0674900A1 (fr) Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA
LU88001A1 (fr) Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
TW202344255A (zh) 包含別孕烷醇酮(Brexanolone)、加那索醇酮(Ganaxolone)或祖拉諾醇酮(Zuranolone)的醫藥組合物及其用途
EP0288336B1 (fr) Dispositif auto-adhésif d'administration d'un principe actif par voie percutanée
WO2015002435A1 (ko) 다중층상 유화물 구조의 경피약물전달시스템
TWI341731B (en) Process of lyophilization for the preparation of piroxicam: β-cyclodextrin inclusion compound
JPS61118315A (ja) ステロイド−17−モノエステル含有クリ−ム剤
US5760009A (en) Spirostanyl glycosidal crystalline monohydrate
FR2719770A1 (fr) Système matriciel pour administration transdermique d'ibuprofène et procédé de préparation.
US3764616A (en) 21-phosphate esters of 17{60 -acyloxy-21 hydroxy steroids of the pregnane series
FR2510582A1 (fr) Steroides esterifies en la position 17 et thio-esterifies en la position 21, leur procede de preparation et leur application comme medicament
US4780460A (en) Glycoesters of estradiol and estriol
EP1121100B1 (fr) Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
WO2003013427A2 (en) A method for preparing fluticasone derivatives
KR100788449B1 (ko) 덱시부프로펜 현탁원료 및 현탁액제의 제조방법
JPS63218663A (ja) ジヒドロピリジン−ヒドロキシプロピルシクロデキストリン包接複合体
EP0950050A1 (fr) Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
y Sosa et al. Non-polymeric Microspheres for the Therapeutic Use of Estrogens: An Innovative Technology
JPH0129199B2 (es)
IL101260A (en) Crystallization of organic substances of steroidal origin and the thus obtained compounds
MXPA00008314A (es) Particulas configuradas estables de compuestos organicos cristalinos
JPS60116699A (ja) ステロイド−環状(1→2)−β−D−グルカン包接化合物およびその製法
BE631542A (es)